prazosin / Generic mfg. - LARVOL DELTA

Aerobic Exercise Prevents the Loss of Endogenous Pain Modulation in Male and Female Rats with Traumatic Brain Injury. (PubMed, J Neurotrauma) - "These gains were reversed by administration of the α1-adrenoceptor (α1-AR) antagonist, prazosin...These results demonstrate that exercise is a promising treatment for chronic nociception after TBI in both male and female rats. It also highlights that dysfunction of endogenous pain modulatory pathways in male TBI rats involving a transition from NA to serotonergic antinociception can be blocked by exercise, possibly by reducing axonal loss."

Journal • Preclinical • CNS Disorders • Inflammation • Musculoskeletal Pain • Pain • Vascular Neurology

A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes. (PubMed, Sleep Med) - "Positive airway pressure therapy successfully treated sleep disordered breathing while pitolisant and solriamfetol produced the most durable improvement in daytime sleepiness. Together melatonin plus clonazepam reduced parasomnia frequency and severity. Several other agents (including prazosin, sodium oxybate, paroxetine, and modafinil) were tried and discontinued for limited benefit or adverse effects...The observation may justify further study of metabolic and incretin-related pathways in sleep-related eating behaviors. Overall, this case highlights the complexity of overlapping sleep-wake disorders, the need for individualized pharmacologic sequencing, and a potential emerging role for GLP-1 agonists in SRED."

Journal • CNS Disorders • Delayed Sleep Phase Disorder • Excessive Daytime Sleepiness • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Sleep Wake Cycle Disorder

Brain Blood Vessel Responses to Changes in Blood Flow (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: Jan 2027 ➔ May 2027 | Trial primary completion date: Jan 2027 ➔ May 2027

Trial completion date • Trial primary completion date

Predominant α₂-adrenoceptor control of chelonian systemic resistance arteries provides a mechanistic basis for the cardiovascular effects of α₂-agonist sedation. (PubMed, Am J Physiol Heart Circ Physiol) - "The effects of α₂-adrenoceptor antagonism with vatinoxan and α₁-adrenoceptor antagonism with prazosin were also assessed...This adrenergic organization differs from the α₁-dominant vascular regulation typical of mammals and identifies chelonian arteries as a useful comparative model for α₂-adrenoceptor-mediated vascular control. The findings also provide a mechanistic basis for the peripheral vascular component of the cardiovascular response to α₂-adrenoceptor agonist sedation in chelonians."

Journal • Anesthesia • Cardiovascular

Intra-Accumbal Infusions of an α2-Adrenoceptor Agonist and an α2-Adrenoceptor Antagonist Respectively Inhibit and Enhance Acetylcholine but Not Dopamine Efflux in the Nucleus Accumbens of Freely Moving Rats. (PubMed, Synapse) - "Neither the α1-agonist methoxamine (0.24 pmol) nor the α1-antagonist prazosin (6.0 pmol) altered accumbal ACh levels...These findings indicate that RX 821002 enhances ACh efflux in the NAc by blocking accumbal α2-adrenoceptor-mediated inhibition of ACh release. Given that reduced accumbal ACh levels have been implicated in cognitive impairment, systemic administration of α2-adrenoceptor antagonists should be investigated for their potential to improve such deficits in experimental models."

Journal • Preclinical • Alzheimer's Disease • Cognitive Disorders

A practical approach to estimate the potency of an antagonist in a functional experiment with isolated preparations of rat aorta. (PubMed, Adv Physiol Educ) - "Alternative methods, such as the Cheng-Prusoff approach, have been proposed to estimate the value of Kb in functional studies, a parameter that represents the affinity of the antagonist for one receptor. Based on these approaches, the present study proposed an experimental protocol designed to help students understand the concept of antagonist potency using phenylephrine and prazosin in isolated rat aorta preparations."

Journal • Preclinical

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests (clinicaltrials.gov) - P3 | N=87 | Active, not recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Jun 2026 ➔ Dec 2026

Biomarker • Trial completion date • Cardiovascular • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Prazosin-Related Reductions in Daily Craving Mediate Treatment-Related Daily Alcohol Use Outcomes in Alcohol Use Disorder. (PubMed, Biol Psychiatry Glob Open Sci) - "Utilizing an intensive daily longitudinal design and random slope modeling, the current study examined daily craving change as a dynamic process associated with changes in daily alcohol intake during treatment. The findings support prazosin's anticraving mechanism of action underlying prazosin-related reductions in alcohol intake."

Clinical • Journal • Addiction (Opioid and Alcohol)

Prazosin Monotherapy for Adolescent Posttraumatic Stress Disorder: A Case Report and Narrative Review. (PubMed, Focus (Am Psychiatr Publ)) - "This case is contextualized within a narrative review of the pediatric prazosin literature, and highlights pharmacologic rationale, safety considerations, and clinical utility. The findings underscore the central role of sleep disturbances as a pivotal treatment target in pediatric PTSD and support further research into prazosin's therapeutic potential in this population."

Journal • Monotherapy • CNS Disorders • Mood Disorders • Pediatrics • Post-traumatic Stress Disorder • Sleep Disorder

Predicting pHmax and Salt Disproportionation Risk for Basic Drugs. (PubMed, Mol Pharm) - "Disproportionation risk levels were systematically defined based on development requirements and were exemplified using model HCl salts (sertraline, prazosin, phenazopyridine, and pioglitazone) across a wide pHmax range. Notably, the risk level increases more sharply with the pH difference (pHee - pHmax) for highly hygroscopic excipients. A prediction workflow for disproportionation risk level is proposed based on the above correlation and the self-disproportionation type of pharmaceutical salts."

Journal

Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States. (PubMed, Am J Ophthalmol) - "AACC following pharmacologic dilation was rare and occurred predominantly among patients with anatomical risk factors, supporting the safety of dilation in routine clinical care. Medication-associated risk signals were observed across commonly prescribed drugs at the population level, including previously unreported associations, highlighting the importance of proactive ocular risk assessment and medication reconciliation in anatomically predisposed patients. Novel medication associations with calcium channel blockers, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation."

Journal • Glaucoma • Ophthalmology

Pulmonary Aspiration During Electroconvulsive Therapy in a Patient on Multiple Psychotropic Medications: A Case Report and Risk-Stratified Approach to Preprocedural Gastric Ultrasound. (PubMed, J ECT) - "The cumulative anticholinergic burden of his medication regimen, including clozapine, benztropine, quetiapine, paliperidone, and prazosin, combined with the recognized association between psychiatric illness and disordered gastric motility, likely contributed to retained gastric contents at the time of induction. We review the limitations of fasting-based risk assessment, the prevalence of residual gastric content in appropriately fasted patients, the evidence supporting POC gastric ultrasound as a decision-support tool, and the practical constraints of equipment availability and operator training. We propose a risk-stratified approach in which preprocedural POC gastric ultrasound is recommended for ECT patients with one or more risk factors for delayed gastric emptying-rather than as a universal, mandatory examination."

Journal • Anesthesia • Gastrointestinal Disorder • Mental Retardation • Psychiatry

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: University of Wisconsin, Madison | Trial completion date: Dec 2026 ➔ May 2027 | Trial primary completion date: Dec 2026 ➔ May 2027

Trial completion date • Trial primary completion date

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data. (PubMed, Med J Aust) - "Young women predominated, likely due to expanded off-label (but accepted) psychiatric use of prazosin. Better evidence on benefits of off-label use is needed to justify increasing risks."

Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Rewiring ALS by modulating the autophagy receptor SQSTM1. (PubMed, Stem Cell Reports) - "In this issue, Roussange et al., show that reverse phenotypic mapping could uncover therapeutic gene expression signatures. Using this approach, they identified prazosin, which increases SQSTM1 expression and rescues disease phenotypes in iPSC-derived motor neurons and zebrafish model of amyotrophic lateral sclerosis with SQSTM1 haploinsufficiency."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Genetic Disorders • SQSTM1

Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics. (PubMed, Stem Cell Reports) - "One hit, increased SQSTM1 expression induced by prazosin, was further validated in FTD/ALS type 3 models caused by SQSTM1 haploinsufficiency, including patient-derived fibroblasts, SQSTM1-depleted hiPSC-derived motor neurons, and a zebrafish model. Extending this paradigm could involve testing diverse cell types and larger drug libraries."

Gene Signature • Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Genetic Disorders • SQSTM1

Using Clonidine Suppression Testing to Distinguish Essential Hypertension and Pheochromocytoma (ENDO 2026) - "Blood pressure was managed with prazosin, amlodipine and metoprolol. Using clonidine suppression testing confirmed diagnosis of pheochromocytoma in this patient with mildly elevated catecholamines."

Cardiovascular • Endocrine Disorders • Hypertension • Hypotension • Solid Tumor

When Fatigue Becomes Fatal: Severe Hypothyroidism Presenting as Hypertensive Urgency (ENDO 2026) - "Levothyroxine was initiated at 1.6 μg/kg/day (150 μg daily). Targeted antihypertensive therapy with nifedipine and prazosin was employed to reduce vascular resistance... This case exposes an interesting paradox: profound hypothyroidism presenting as hypertensive urgency. Severe T3 depletion can present as primary hypertension and drive life-threatening blood pressure elevations. Recognition of hypothyroidism as a reversible cause of secondary hypertension is critical, as thyroid hormone replacement alone may substantially normalize blood pressure and prevent unnecessary long-term antihypertensive therapy."

Cardiovascular • Constipation • Dyslipidemia • Endocrine Disorders • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology

Preoperative Belzutifan for Recalcitrant Hypertensive Emergency in Secretory Noradrenergic Paraganglioma (ENDO 2026) - "Over 12 days, treatment with multiple medications (losartan 50mg daily, prazosin 1mg BID, nifedipine 90mg daily, spironolactone 75mg daily, and carvedilol 6.25mg BID) failed to prevent intermittent hypertensive episodes (SBP>190 mmHg)...Over the next 18 days, despite aggressive pharmacologic therapy (phenoxybenzamine 40mg QID, valsartan 160mg BID, hydralazine 75mg daily, carvedilol 12.5mg BID, and spironolactone 50mg daily), labile blood pressure prevented surgical intervention... Belzutifan provided acute blood pressure control for paraganglioma related cardiovascular lability with hypertensive crises, allowing for definitive surgical treatment. To our knowledge, this is the first reported use of Belzutifan as a preoperative agent. Whether Belzutifan is uniquely beneficial as an anti-hypertensive in the setting of HIF-2α mutation-associated PPGL, or has broader utility remains undetermined."

Cardiovascular • Hypertension • Solid Tumor • EPAS1 • SDHB • SYP

Pheochromocytoma Presenting with Hypotension and Cardiogenic Shock: A Diagnostic Paradox (ENDO 2026) - "She was eventually discharged home on prazosin 1mg daily...She was on Doxazosin for a total period of 16 weeks, and the maximum tolerated dose was 3 mg twice daily prior to undergoing an adrenalectomy with complete tumor resection...In this patient, clinical instability and enlarging adrenal mass on imaging served as strong diagnostic indicators. This case illustrates a rare clinical scenario in which clinical presentation and adrenal imaging findings outweighed biochemical work-up given the known limitation of metanephrines interpretation during shock state."

Cardiomyopathy • Cardiovascular • Cough • Developmental Disorders • Endocrine Disorders • Heart Failure • Hypertension • Hypotension • Mental Retardation • Pulmonary Disease • Respiratory Diseases • Solid Tumor

A Pragmatic Algorithm for Selecting Psychopharmacology Treatment for Secondary Insomnia. (PubMed, J Clin Psychopharmacol) - "Insomnia is often multifactorial. When it is secondary to psychiatric disorders, there may be evidence-supported psychopharmacology approaches rather than just targeting the insomnia solely as a symptom."

Journal • CNS Disorders • Depression • General Anxiety Disorder • Insomnia • Major Depressive Disorder • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder

Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis (clinicaltrials.gov) - P2 | N=112 | Completed | Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Unknown status ➔ Completed

Trial completion • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

A cluster out of the blue: Drug-induced cluster headache (AHS 2026) - "After stabilization with IV nitroglycerine, oral hydralazine 37.5 mg thrice daily was added to clonidine, metoprolol, amlodipine, and prazosin... This case describes a de novo, cluster-like headache temporally associated with nitroglycerin infusion and hydralazine initiation and resolving rapidly after drug withdrawal, suggesting a possible drug-triggered cluster headache. Clinicians should consider the possibility of drug-induced cluster headache in patients with recent drug modifications. New-onset cluster headache phenotypes in older individuals, especially females, warrant careful evaluation for secondary causes, including medication-related triggers."

CNS Disorders • Pain

Restoration of Glymphatic Flow by α1-noradrenergic Antagonism Alleviates Facial Allodynia in Headache Models (AHS 2026) - " Here we show that prazosin (PZN), an α1-noradrenergic receptor antagonist, restores glymphatic flow and treats facial allodynia induced by calcitonin gene-related peptide (CGRP) and a nitric oxide donor in mice. In contrast, propranolol, a β-noradrenergic receptor antagonist, was ineffective... Overall, these findings indicate that targeting α1-noradrenergic receptors to enhance glymphatic flow may offer a therapeutic strategy for treating migraine and PTH."

CNS Disorders • Migraine • Pain • Vascular Neurology

Prazosin for post-traumatic nightmares: A clinical audit in acute public psychiatric unit patients. (PubMed, Australas Psychiatry) - "Prazosin was discontinued in 12 of 114 patients, most commonly due to dizziness or hypotension.ConclusionsPrazosin was associated with clinically and statistically significant improvements in PTNs in this cohort, noting confounding variables and subjective assessment with no control group. Findings support clinical use while underscoring the need for larger, prospective Australian trials."

Journal • CNS Disorders • Hypotension • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry